1. IDEAYA announces participation in investor relations events in September 2025. 2. Key events include the Cantor Global Healthcare Conference and R&D Day. 3. R&D Day will showcase clinical data updates and growth strategies. 4. The events will highlight collaborations with industry experts. 5. Investors can access live webcasts of the presentations.
The upcoming events present a platform for significant updates, positively affecting investor perception. Historically, investor engagement events lead to price increases when clinical data is favorable.
These investor events are crucial for positioning and market sentiment. Positive discussions and data releases can significantly influence stock value.
The events are scheduled for early September, likely generating immediate interest. Past examples show similar events boost stock prices before and shortly after the announcements.
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events.
Cantor Global Healthcare Conference 2025
Wednesday, September 3rd, 2025 at 9:10 AM ET
IDEAYA Biosciences 10-Year Anniversary R&D Day
Monday, September 8th, 2025 at 8:00 AM ET
Morgan Stanley 23rd Annual Global Healthcare Conference
Tuesday, September 9th, 2025
A live audio webcast of the conference events, as permitted by the conference host, will be available at the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 18, 2025.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-september-2025-investor-relations-events-302537011.html
SOURCE IDEAYA Biosciences, Inc.